PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
PHASE3CompletedINTERVENTIONAL
Enrollment
217
Participants
Timeline
Start Date
July 31, 2007
Primary Completion Date
May 31, 2009
Study Completion Date
October 31, 2009
Conditions
Psoriasis
Interventions
BIOLOGICAL
infliximab
Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
All Listed Sponsors
lead
Centocor Ortho Biotech Services, L.L.C.
INDUSTRY
NCT00527072 - PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept | Biotech Hunter | Biotech Hunter